This product was developed by |
Camelid single domain antibodies (sdAbs) consist only of one antigen binding site of an Alpaca heavy chain antibody. With only ~15 kDa, these Tags are about 10-times smaller than conventional IgG antibody molecules.
Cat. No. N3501-At488-L |
200 µl purified antibody, lyophilized from PBS, fluorescence-labeled with ATTO® 488.
For many of the fluorescence labeled antibodies conjugated to ATTO® dyes from ATTO®488, ATTO®565, ATTO®647N and ATTO®594 dyes are suitable for Stimulated Emission Depletion (STED) microscopy which allows higher resolution imaging compared to confocal laser scanning microscopy. This product or portions thereof is manufactured under license from ATTO-TEC GmbH. Reconstitute immediately upon receipt! Avoid bright light when working with the antibody to minimize photo bleeching of the fluorescent dye. |
Storage | –80°C for up to 12 month |
Applications |
Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.', $event)" style="cursor: help;">ICC: 1 : 500 Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IHC: not tested yet Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-P: not tested yet |
Label | ATTO 488, one fluorophore coupled to one FluoTag |
Clone | W25 |
Subtype | single domain |
Immunogen | recombinant S1-Spike protein from SARS-CoV-2 (UniProt Id: P0DTC2) |
Specificity | RBD of S1 protein from SARS-CoV-2 |
This anti-S1 SARS-CoV-2 nanobody was developed by the team of Alejandro Rojas-Fernandez at the Institute of Medicine from the Universidad Austral de Chile. NanoTag acquired the exclusive license to produce this nanobody and make it available or research and development purposes. The FluoTag-Q anti-S1 SARS-CoV-2 is based on the W25 clone, which has a sub-nanomolar affinity for the SARS-CoV-2 S1 protein receptor binding domain (RBD) and can neutralize infections as it efficiently competes with ACE-2 receptor binding.
Unlabeled variants and several modifications of sdAbs like biotin, fluorophore or DBCO conjugation are available.
In FluoTag®-Q each fluorophore is coupled to exactly one FluoTag, which in turn binds to its target molecule in a monovalent fashion. The high binding affinity and a coupling efficiency of > 95% guarantees a highly linear relation between the number of target molecules and the intensity of fluorescence. This enables a direct count of the target molecule of interest. The fluorophore is located exceptionally close to the recognized epitope (< 1.5 nm), which is ideal for all microscopy techniques.